[Glucocorticoid and Bone. Beneficial effect of teriparatide on fracture risk as well as bone mineral density in patients with glucocorticoid-induced osteoporosis].
- Published Article
- Publication Date
Sep 01, 2014
Bone metablism of glucocorticoid-induced osteopororsis (GIO) is characterised by transient increase in bone resorption and persistent suppression of bone formation caused by glucocorticoid. Teriparatide is an ideal drug for GIO, because of antagonistic effect against that pathophysiological conditions. Based on new findings of treatment for GIO around the world, teriparatide was selected as one of alternative drugs of the first line agents for GIO in revised version of the guidelines on the management and treatment of GIO of the Japanese Society for Bone and Mineral Research : 2014 update.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/05/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/25177011